We are live on
!
Find out more
Corvus Pharmaceuticals
CRVS
CRVS
57 hedge funds and large institutions have $279M invested in Corvus Pharmaceuticals in 2018 Q2 according to their latest regulatory filings, with 8 funds opening new positions, 29 increasing their positions, 12 reducing their positions, and 6 closing their positions.
New
Increased
Maintained
Reduced
Closed
142% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 12
33% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 6
4% more funds holding
Funds holding: 55 → 57 (+2)
2.1% more ownership
Funds ownership: 86.65% → 88.75% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
3% less capital invested
Capital invested by funds: $288M → $279M (-$9.17M)
Holders
57
Holders Change
+2
Holders Change %
+3.64%
% of All Funds
1.3%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
8
Increased
29
Reduced
12
Closed
6
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
CI
Cowen Inc
New York
|
+$5.97M |
| 2 |
BlackRock
New York
|
+$4.27M |
| 3 |
IBT
International Biotechnology Trust
London,
United Kingdom
|
+$908K |
| 4 |
State Street
Boston,
Massachusetts
|
+$783K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$684K |
Top Sellers
| 1 |
Millennium Management
New York
|
-$2.9M |
| 2 |
JP Morgan Chase
New York
|
-$1.16M |
| 3 |
Renaissance Technologies
New York
|
-$1.14M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$903K |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$824K |
